Chronic Kidney Disease

Hosts break down data from the CONFIDENCE trial on the safety and efficacy of finerenone plus empagliflozin in patients with T2D and CKD.

Brendon Neuen, MBBS, PhD, is joined by Rajiv Agarwal, MD, MS to explore the concept of simultaneous initiation of SGLT2i and nsMRA in CKD and T2D.

Combination therapy with finerenone and empagliflozin significantly reduces urinary albumin levels in CKD patients.

An overview of the 7 presentations included as late-breaking clinical trials at ERA 2025.

The month in review spotlights renal FDA news and novel research about CKD and social determinants of health in kidney care.

From 1990-2021, global CKD-related deaths and DALYs attributable to physical inactivity increased, especially in low-SDI regions and among females.

Prophylactic treatment with IV magnesium led to a lower risk of cisplatin-associated AKI in patients with cancer undergoing cisplatin chemotherapy.

Several mobile apps effectively improved medication adherence in patients with CKD, posing important implications for their impact on clinical outcomes.

Black patients disproportionately started dialysis at low-quality facilities and were less likely to have nephrologists with high-quality primary facilities.

An audio recap of the top 5 stories in healthcare news from the week of 03/31-04/06.

Most patients preferred OLC over their previous phosphate binder, and pill number and size were identified as barriers to phosphate binder adherence.

Electronic health interventions improved medication adherence in kidney transplant recipients, with potential implications for improving patient outcomes.

In this episode, hosts break down the STRIDE and SOUL trials presented at the American College of Cardiology 2025 Annual Scientific Sessions.

Study findings suggest significant socioeconomic disparities in preemptive kidney transplantation rates in children and the need for targeted interventions.

Our Q1 recap for nephrology spotlights regulatory updates, new clinical trial data, and advancements in xenotransplant.

Using CURE-CKD Registry data, the analysis showed relatively rapid-onset CKD was common in people with prediabetes, especially with hypertension or ASCVD.

The March 2025 month in review spotlights a new episode of Crisis Point about CKD for National Kidney Month and renal FDA news.

Study findings suggest COVID-19 is linked to a greater risk of long-term kidney dysfunction and new-onset advanced CKD than influenza.

The first quarter of 2025 saw approvals in diabetes, depression, kidney disease, and pain, among others. Read more about high-impact approvals of Q1 now.

Four-year results from SOUL at ACC.25 were the first to test the cardiovascular benefits of an oral GLP-1 RA in high-risk type 2 diabetes.

The March 2025 approval for iptacopan marks the first for C3 glomerulopathy and is based on the APPEAR-C3G trial.

Patients with CKD undergoing radical prostatectomy for prostate cancer experienced greater rates of adverse in-hospital outcomes.

Retransplantation in elderly patients was associated with a higher risk of DWFG but similar death-censored outcomes to primary transplantation.

The Kidney Transplant Fast Track evaluation approach was associated with a higher likelihood of waitlisting and fewer disparities by race or ethnicity.

Psychosocial interventions reduced depressive symptoms in CKD but did not have a significant impact on patients’ quality of life.